Accurate and timely diagnosis remains the greatest challenge in the CIDP space, as the condition often mimics other forms of peripheral neuropathy. However, recent advancements in neuromuscular ultrasound and high-resolution magnetic resonance neurography are allowing clinicians to visualize nerve swelling and demyelination with unprecedented clarity. These imaging techniques, combined with the discovery of specific autoantibody biomarkers—such as those targeting the "nodes of Ranvier"—are enabling a more definitive diagnosis and helping to distinguish between "typical" and "atypical" forms of the disease. Early identification is critical, as it allows for the initiation of therapy before permanent nerve damage occurs.

Insights from the Chronic Inflammatory Demyelinating Polyneuropathy Market indicate that the diagnostic segment is evolving toward a "multi-modal" approach. The integration of digital health tools, such as wearable sensors that track gait and muscle strength, is providing neurologists with real-time data on disease progression and treatment efficacy. Hospitals and specialty clinics are investing heavily in these diagnostic infrastructures to improve patient outcomes and reduce the rate of misdiagnosis. As global awareness of rare autoimmune neuropathies grows, the demand for these advanced diagnostic services is rising, particularly in emerging markets where healthcare infrastructure is rapidly modernizing.